InsiderClue
Insiders · Profile

Newton Charles W.

Director at Keros Therapeutics · Chief Financial Officer at Lyell Immunopharma. Filing since 17 Mar 2025. CIK 0001866219

KROS Keros Therapeutics, Inc. Director · 2 trades LYEL Lyell Immunopharma, Inc. Chief Financial Officer · 4 trades
Company
Date
Role
Action
Shares
Amount
Of holding
KROS Keros Therapeutics, Inc.
18 Aug 2026
Director
Sold on a plan
551
$5.68K
4.4%
KROS Keros Therapeutics, Inc.
11 Jun 2026
Director
Sold on a plan
550
$5.52K
4.2%
LYEL Lyell Immunopharma, Inc.
21 Aug 2025
Chief Financial Officer
Sold at will
1,453
$15.32K
8.7%
LYEL Lyell Immunopharma, Inc.
12 Aug 2025
Chief Financial Officer
Sold at will
136
$1.41K
1.5%
LYEL Lyell Immunopharma, Inc.
11 Aug 2025
Chief Financial Officer
Sold at will
131
$1.38K
1.5%
LYEL Lyell Immunopharma, Inc.
17 Mar 2025
Chief Financial Officer
Bought
200,000
$111.62K
opened
6 decisions on file.